Abstract: The present invention pertains to methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby. The coating solution described herein comprises one or more antimicrobial peptides (AMPs) dissolved in a buffer containing an anionic surfactant, wherein the AMPs are amphipathic and cationic.

Abstract: The present disclosure relates to mir-17˜92 as a candidate therapeutic or diagnostic target of motor neuron (MN) degeneration diseases. Expression of mir-17˜92 is sustained throughout adulthood in spinal MNs and specifically decreases before the onset of MN loss in SOD1G93A mice. Accordingly, mir-17˜92 can be used as a candidate therapeutic target for ALS.

Abstract: Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5?-glycylcarbonyl-N6-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5?-deoxy-5?-(N?-glycylureido)-N6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.

Abstract: The present invention relates to a method for promoting growth of plants. Particularly, the method of the present invention features overexpression of a calcineurin B-like (CBL) interacting protein kinase15 (CIPK15) having an isoleucine (Ile) residue at position 48 (e.g. a CIPK15 from rice) in plants which can promote growth of the plants. The present invention also relates to a recombinant construct comprising a nucleic acid encoding the CIPK15 operably linked to a promoter. The present invention further relates to a transgenic plant overexpressing the CIPK15 exhibiting improved growth compared to a non-transgenic plant counterpart.

Abstract: Methods and computer-implemented methods are used to predict a risk of cardiovascular disease by using a machine learning mode to analyze a relationship between the occurrence of cardiovascular disease and the health data of patients.

Abstract: Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.

Abstract: Provided herein are compounds of Formula (I). The disclosure provides new compounds, compositions, and methods for treating, delaying, and/or preventing the adverse effects of proliferative diseases, such as cancers including, for example, lung cancer, breast cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, head and neck cancer, or leukemia (e.g., cancer resistant to treatment by one or more microtubule-targeting agents (e.g., cancer resistant to multiple drugs associated with P-glycoprotein (P-gp) overexpression)). Provided are methods of inhibiting polymerization of a cancer cell microtubule in a subject in need thereof or a cell, tissue, or biological sample, binding ?-tubulin, inhibiting microtubule assembly and, inducing apoptosis in a cancer cell resistant to multiple drugs in a tissue, biological sample, or subject. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for treating any of the target diseases described herein.

Abstract: A method of generating an internally fixed lipid vesicle, comprising: providing a precursor lipid vesicle that contains an aqueous interior enclosed by a lipid membrane, wherein the lipid membrane of the precursor lipid vesicle is non-permeable to a crosslinker; permeabilizing the lipid membrane transiently to generate a permeable vesicle; contacting the permeable vesicle with an inactive activatable crosslinker, whereby the inactive activatable crosslinker enters the permeable vesicle; allowing the permeable vesicle to return to a non-permeable vesicle; removing any extravesicular crosslinker; and activating the inactive activatable crosslinker to allow crosslinking to occur inside the non-permeable vesicle, whereby an internally fixed lipid vesicle is generated.

Abstract: Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.

Abstract: The present invention generally relates to a method for treating a demyelinating condition, in particular, by administering a combination comprising therapeutically effective amounts of a Rho-associated protein kinase (ROCK) inhibitor, a cyclin-dependent kinase (CDK) inhibitor, and a cyclic adenosine monophosphate (cAMP) activator to a subject in need thereof.

Abstract: A method and apparatus for surface plasmon resonance imaging are provided for imaging the surface plasmon resonance signals caused by the interaction of biomolecules. In particular, the method and apparatus can image the slightly spectral change in a surface plasmon resonance mode by comparing the light intensities of two bands in the frequency domain of the surface plasmon.

Abstract: Disclosed herein is a recombinant polypeptide comprising 1 to 20 copies of an IL-17RB inactivation site (IRIS) sequence. Also disclosed herein is the use of the recombinant polypeptide in the preparation of a conjugate for the treatment of cancers.

Abstract: An antimicrobial peptide, the peptide comprising 2 to 20 variable domains, each variable domain is a sequence of 2 to 20 consecutive basic amino acids, wherein (a) the variable domains are separated from each other by a variable linker, (b) the variable linker can have 1 to 20 any amino acids other than two or more consecutive basic amino acids, and (c) the peptide has no more than 100 amino acids.

Abstract: Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.

Abstract: The present invention is directed to methods of treating hypertriglyceridemia or hypertriglyceridemia-related diseases in a subject by using recombinant PRAP1 polypeptides. According to some embodiments of the present disclosure, the subject is a human, in which the recombinant PRAP1 polypeptide comprises the amino acid sequence 100% identical to SEQ ID NO: 1 or 2. According to certain embodiments of the present disclosure, the subject is a mouse, in which the recombinant PRAP1 polypeptide comprises the amino acid sequence 100% identical to SEQ ID NO: 3 or 4.

Abstract: The present invention relates to a method for treating autism spectrum disorders (ASD) or ASD-like symptom, particularly by administering a zinc ion source and/or a serine component e.g. D-serine or its precursor/analogue, optionally in combination with a mixture of branched-chain amino acids (BCAAs). The present invention also relates to a combination, kit or composition for performing the method for treatment as described herein. Further described is use of a zinc ion source and/or a serine component and optional BCAAs for manufacturing a medicament for treating a symptom or disease characteristics associated with ASD or ASD-associated disorder or as a food supplement for ameliorating relevant symptoms in a subject in need thereof. The present invention further provides an animal model for autistic spectrum disorder (ASD) with deficient CTTNBP2 gene, and a method for identifying an ingredient effective in the treatment of ASD by using such animal model.

Abstract: Disclosed herein is an integrated microfluidic chip for detecting cancerous cells, particularly, cholangio-cancerous cells, from a biological sample. Also disclosed herein is a method of detecting cholangio-cancerous cells from a biological sample.

Abstract: Disclosed herein are novel polyhydroxylated indolizidine and pyrrolizidine derivates and methods for using the same in the treatment of cancer. The present polyhydroxylated indolizidine and pyrrolizidine derivates has the structure of formula (I), wherein: X is O or b and c are independently an integral of 0 or and 1; R is selected from the group consisting of H, C1-6 alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, heteroaralkenyl, beteroaralkynyl, heterocyclyl, alkoxy, aryloxy, and sulfonyl.

Abstract: The present invention provides a lectin from Crenomytilus grayanus or Mytilus trossulus as diagnostic reagents for IgA nephropathy. The present invention also provides a diagnostic kit for detecting Galactose-deficient IgA1 (Gd-IgA1), comprising RussiaSea-001 (also called as CGL) isolated from Crenomytilus grayanus or RussiaSea-002 (also called as MTL) isolated from Mytilus trossulus. The present invention further provides a method for detecting Gd-IgA1 using RussiaSea-001 or RussiaSea-002.

Abstract: The present invention relates to antibodies that bind to ENO1 and applications thereof. The applications encompass therapies and diagnostics of diseases or disorders associated with ENO1 activation and progression thereof using such antibodies. Specifically, the antibodies of the present invention bind to ENO1 on the surface of cancer cells and are useful in reducing cancer cell growth and metastasis and prolonging survival time. The antibodies of the present invention may also be used in detecting ENO1, diagnosis and prognosis of cancer and monitoring cancer progression. The present invention also provides a method for screening for a candidate agent for cancer therapy.